Affiliation: Targacept Inc
- Nicotinic receptors as targets for therapeutic discoveryPm Lippiello
Targacept, Inc, 200 East 1st Street, Suite 300, Winston Salem, NC 27101, USA 1 336 480 2100 1 336 480 2107
Expert Opin Drug Discov 2:1185-203. 2007..Clinical proof-of-concept is rapidly emerging and will solidify the position of this new therapeutic approach...
- Nicotinic cholinergic antagonists: a novel approach for the treatment of autismP M Lippiello
Preclinical Research, Targacept, Inc, Winston Salem, NC 27101, USA
Med Hypotheses 66:985-90. 2006..Clearly there is a need for carefully controlled clinical studies with novel selective NNR antagonists to explore their potential as a new and exciting approach for the treatment of autism...
- Ispronicline: a novel alpha4beta2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective propertiesPatrick Lippiello
Preclinical Research, Targacept Inc, Winston Salem, NC 27101, USA
J Mol Neurosci 30:19-20. 2006..Thus, a challenge in nAChR drug design and development has been the reduction of undesirable effects that result from activity at specific nAChRs in the CNS and PNS, including cardiovascular toxicity, emesis, seizures, and hypothermia...
- TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activityPatrick M Lippiello
Targacept, Inc, Winston Salem, North Carolina 27101, USA
CNS Neurosci Ther 14:266-77. 2008....